HGF and lung cancer: Another multispecific DARPin targeting VEGF and hepatocyte growth factor (HGF), while also binding to human serum albumin (HSA) for increased half‐life [46], is currently tested in combination with a tyrosine kinase inhibitor in a clinical trial for patients with non‐small cell lung cancer (NCT03418532).